SecurAcath® Receives Boost from New NHS MedTech Funding Mandate

PLYMOUTH, Minn.--()--Interrad Medical, a privately held medical device company, announces the SecurAcath is one of only four medical technologies to be included in the new MedTech Funding Mandate program.

The NHS Long Term Plan outlined how research and innovation would drive better outcomes and experience for patients. An important element of this was a MedTech Funding Mandate to accelerate the uptake of selected National Institute for Health and Care Excellence (NICE)-approved, cost-saving medical devices.

NHS reviewed all NICE medical technologies guidance (MTGs) and NICE diagnostics guidance (DGs) published by 30 June 2020 to identify devices, diagnostics or digital products that: Are effective, deliver material savings to the NHS, are cost-saving in-year, and are affordable to the NHS.

The Mandate calls out the SecurAcath Clinical Benefits:

“SecurAcath is easy to insert, well tolerated, associated with a low incidence of catheter-related complications and does not usually need to be removed while the catheter is in place. Further clinical benefits include no interruptions or delays from the catheter becoming dislodged. Fewer repeat procedures are needed because SecurAcath improves vessel preservation and reduces need for re-insertions. There are also fewer complications such as dislodgements, migration, thrombosis and infection.”

The Mandate also specifies the important Patient Benefits SecurAcath provides

  • No risk of medical adhesive-related skin injury.
  • No requirement for frequent adhesive fixing changes.
  • Reduced risk of interruption to treatment.
  • Reduced risk of catheter-related infection.
  • Reduced pain on insertion and while in situ.
  • Reduced need for unplanned catheter removal and re-insertion.

“We are pleased the SecurAcath was selected for the first-ever NHS Funding Mandate. We truly appreciate the NHS support of the use of the innovative SecurAcath device to improve patient outcomes and save money," commented Joe Goldberger, President and CEO of Interrad Medical.

The SecurAcath is the only subcutaneous catheter securement device that lasts the life of the line and can significantly reduce risk of catheter-related infections and other complications, dramatically decrease catheter dislodgement and migration, decrease catheter replacement costs, and lower total cost of patient care.

About Interrad Medical, Inc.

Plymouth, Minnesota-based Interrad Medical, Inc. is a developer, manufacturer and marketer of medical devices designed for minimally-invasive interventional and surgical procedures. Learn more at

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, reimbursement policies and commercialization of new technologies.


Jeff Killion, Chief Marketing Officer

Release Summary

SecurAcath® Receives Boost from New NHS MedTech Funding Mandate

Social Media Profiles


Jeff Killion, Chief Marketing Officer